Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL596371 | 1.00 | MEN1 (0.51) | MEN1KMT2ATDP1APPTHRB | |
| SCHEMBL596802 | 0.90 | MEN1 (0.67) | MEN1KMT2ATDP1APPTHRB | |
| SCHEMBL596803 | 0.90 | MEN1 (0.67) | MEN1KMT2ATDP1APPTHRB | |
| SCHEMBL5809509 | 0.80 | RAB9A (0.48) | MEN1KMT2ATDP1APPTHRB | |
| SCHEMBL5809506 | 0.80 | RAB9A (0.48) | MEN1KMT2ATDP1APPTHRB | |
| SCHEMBL3385330 | 0.78 | MEN1 (0.70) | MEN1KMT2ATDP1APPTHRB | |
| SCHEMBL1624756 | 0.78 | MEN1 (0.70) | MEN1KMT2ATDP1APPTHRB | |
| SCHEMBL26730466 | 0.78 | MEN1 (0.70) | MEN1KMT2ATDP1APPTHRB | |
| SCHEMBL10930328 | 0.76 | MEN1 (0.68) | MEN1KMT2ATDP1APPTHRB | |
| SCHEMBL15928995 | 0.75 | PTGS2 (0.39) | MEN1KMT2ATDP1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114858-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114858-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114858-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114857-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114857-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114857-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| EP-1883645-B1 | DERIVATIVES OF 4-OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC (CA) | 2011-06-29 | — | — | EP | disclosed |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-06-02 | — | — | US | disclosed |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-06-02 | — | — | US | disclosed |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-06-02 | — | — | US | disclosed |
| US-20080207564-A1 | Derivaitves of 4-Or 5-Aminosalicylic Acid | ANTIBE THERAPEUTICS INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207564-A1 | Derivaitves of 4-Or 5-Aminosalicylic Acid | ANTIBE THERAPEUTICS INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| EP-1883645-A4 | DERIVATIVES OF 4-OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1883645-A1 | DERIVATIVES OF 4-OR 5-AMINOSALICYLIC ACID | Antibe Therapeutics Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| US-20070197479-A1 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197479-A1 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197479-A1 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2007-08-23 | — | — | US | disclosed |
| WO-2006125293-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270635-A1 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2006-11-30 | — | — | US | disclosed |
| WO-2006125295-A1 | DERIVATIVES OF 4-OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207564-A1 | Derivaitves of 4-Or 5-Aminosalicylic Acid | CBS, SI, TST | MEN1 3842/4885KMT2A 1082/4885TDP1 4495/4885 |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | MEN1 3823/4885KMT2A 2183/4885TDP1 4514/4885 |
| US-20060270635-A1 | Derivatives of 4- or 5-aminosalicylic acid | CBS, SI, APC | MEN1 3823/4885KMT2A 2183/4885TDP1 4514/4885 |
| US-20070197479-A1 | Derivatives of 4- or 5-aminosalicylic acid | CBS, SI, APC | MEN1 3823/4885KMT2A 2183/4885TDP1 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.